Cascaded Multi-view Canonical Correlation (CaMCCo) for Early Diagnosis of Alzheimer's Disease via Fusion of Clinical, Imaging and Omic Features - PubMed (original) (raw)
Cascaded Multi-view Canonical Correlation (CaMCCo) for Early Diagnosis of Alzheimer's Disease via Fusion of Clinical, Imaging and Omic Features
Asha Singanamalli et al. Sci Rep. 2017.
Abstract
The introduction of mild cognitive impairment (MCI) as a diagnostic category adds to the challenges of diagnosing Alzheimer's Disease (AD). No single marker has been proven to accurately categorize patients into their respective diagnostic groups. Thus, previous studies have attempted to develop fused predictors of AD and MCI. These studies have two main limitations. Most do not simultaneously consider all diagnostic categories and provide suboptimal fused representations using the same set of modalities for prediction of all classes. In this work, we present a combined framework, cascaded multiview canonical correlation (CaMCCo), for fusion and cascaded classification that incorporates all diagnostic categories and optimizes classification by selectively combining a subset of modalities at each level of the cascade. CaMCCo is evaluated on a data cohort comprising 149 patients for whom neurophysiological, neuroimaging, proteomic and genomic data were available. Results suggest that fusion of select modalities for each classification task outperforms (mean AUC = 0.92) fusion of all modalities (mean AUC = 0.54) and individual modalities (mean AUC = 0.90, 0.53, 0.71, 0.73, 0.62, 0.68). In addition, CaMCCo outperforms all other multi-class classification methods for MCI prediction (PPV: 0.80 vs. 0.67, 0.63).
Conflict of interest statement
Conflict of interest disclosures for Anant Madabhushi: Inspirata-Stock Options/Consultant/Scientific Advisory Board Member, Elucid Bioimaging Inc.-Stock Options, Siemens, GE-NIH Academic Industrial Partnership.
Figures
Figure 1
The cascade and the modalities for fusion at each level of the cascade were determined on training set and validated on independent testing set. Neurophysiological test scores (ADAS-Cog) are fused with CSF proteomics and APOE at the first level of the cascade to identify healthy controls (HC). At the second level, ADAS-Cog scores are combined with PET to distinguish between patients with Alzheimer’s Disease (AD) and mild cognitive impairment (MCI).
Figure 2
Cascaded multiview canonical correlation analysis (CaMCCo) algorithm for constructing the joint multimodal data fusion and multiclass classification framework.
Figure 3
Performance of single and multi modality cascaded classifiers. Area under the ROC curve (AUC) for prediction of (a) healthy control (HC) from all cognitive impairments, and (b) mild cognitive impairment (MCI) from Alzheimer’s Disease (AD).
References
- McKhann GM, et al. The diagnosis of dementia due to alzheimer’s disease: Recommendations from the national institute on aging-alzheimer’s association workgroups on diagnostic guidelines for alzheimer’s disease. Alzheimer’s & Dementia. 2011;7:263–269. doi: 10.1016/j.jalz.2011.03.005. -DOI -PMC -PubMed
Publication types
MeSH terms
Substances
Grants and funding
- U01 AG024904/AG/NIA NIH HHS/United States
- UL1 TR002369/TR/NCATS NIH HHS/United States
- R01 CA202752/CA/NCI NIH HHS/United States
- R01 CA208236/CA/NCI NIH HHS/United States
- C06 RR012463/RR/NCRR NIH HHS/United States
- U24 CA199374/CA/NCI NIH HHS/United States
- R21 CA179327/CA/NCI NIH HHS/United States
- P30 AG010129/AG/NIA NIH HHS/United States
- R21 CA195152/CA/NCI NIH HHS/United States
- R01 DK098503/DK/NIDDK NIH HHS/United States
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical